Amneal Pharmaceuticals (AMRX) Announces FDA Filing Acceptance of Abbreviated NDA for Naloxone Hydrochloride Nasal Spray, USP, 4mg

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. SPY
3. USO
4. MSFT
5. COST
6. MU
7. IONS
8. CG
9. ORCL
10. RMR

Go back to Amneal Pharmaceuticals (AMRX) Announces FDA Filing Acceptance of Abbreviated NDA for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 2c

March 2, 2023 6:12 AM EST

Amneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $610 million versus the consensus estimate of $579.84 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 revenue of $2.25-2.35 billion, versus the consensus of $2.31... More